AR and prostate carcinoma: In additional clinical prostate cancer datasets, the overexpression of GPI occurs more frequently in androgen/AR-negative neuroendocrine prostate cancer (Supplementary Fig. 4b), suggesting a negative association with the androgen/AR-axis.